29 years of historical data (1997–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Arrowhead Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 55.4x P/FCF, 51% above the 5-year average of 36.6x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $8.7B | $4.6B | $2.3B | $2.9B | $3.5B | $6.5B | $4.3B | $2.8B | $1.6B | $320M | $449M |
| Enterprise Value | $9.3B | $5.2B | $3.1B | $3.1B | $3.5B | $6.3B | $4.2B | $2.6B | $1.6B | $298M | $366M |
| P/E Ratio → | -5186.07 | — | — | — | — | — | — | 40.84 | — | — | — |
| P/S Ratio | 10.48 | 5.56 | 653.40 | 11.92 | 14.33 | 46.84 | 49.29 | 16.46 | 99.33 | 10.19 | 2834.05 |
| P/B Ratio | 16.81 | 9.16 | 12.14 | 9.99 | 8.33 | 15.84 | 9.39 | 11.39 | 16.83 | 3.96 | 4.72 |
| P/FCF | 55.41 | 29.41 | — | — | — | 43.86 | — | 17.26 | — | — | — |
| P/OCF | 48.41 | 25.69 | — | — | — | 37.83 | — | 16.06 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Arrowhead Pharmaceuticals, Inc.'s enterprise value stands at 76.1x EBITDA, 78% above its 5-year average of 42.7x. The Healthcare sector median is 13.8x, placing the stock at a 450% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.30 | 864.39 | 13.05 | 14.22 | 45.69 | 47.90 | 15.15 | 97.60 | 9.48 | 2312.12 |
| EV / EBITDA | 76.09 | 42.73 | — | — | — | — | — | 38.96 | — | — | — |
| EV / EBIT | 94.60 | 37.08 | — | — | — | — | — | 41.79 | — | — | — |
| EV / FCF | — | 33.30 | — | — | — | 42.79 | — | 15.88 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Arrowhead Pharmaceuticals, Inc. earns an operating margin of 11.9%. Operating margins have expanded from -85.2% to 11.9% over the past 3 years, signaling improving operational efficiency. A negative ROE of -0.5% indicates the company is currently destroying shareholder equity. ROIC of 7.2% represents adequate returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.1% | 97.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — |
| Operating Margin | 11.9% | 11.9% | -16927.1% | -85.2% | -73.4% | -107.8% | -105.9% | 36.3% | -346.5% | -117.8% | -51627.1% |
| Net Profit Margin | -0.2% | -0.2% | -16882.4% | -85.3% | -72.4% | -101.9% | -96.1% | 40.3% | -337.3% | -109.5% | -51614.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -0.5% | -0.5% | -250.7% | -58.2% | -42.6% | -32.4% | -24.0% | 40.1% | -61.8% | -39.1% | -79.9% |
| ROA | -0.1% | -0.1% | -62.9% | -28.2% | -25.1% | -22.9% | -19.4% | 29.5% | -50.5% | -29.6% | -62.8% |
| ROIC | 7.2% | 7.2% | -60.1% | -32.3% | -41.7% | -37.9% | -38.6% | 102.4% | -66.6% | -78.2% | -295.1% |
| ROCE | 8.6% | 8.6% | -70.9% | -33.8% | -32.0% | -28.5% | -25.4% | 34.8% | -60.6% | -39.4% | -74.7% |
Solvency and debt-coverage ratios — lower is generally safer
Arrowhead Pharmaceuticals, Inc. carries a Debt/EBITDA ratio of 6.9x, which is highly leveraged (120% above the sector average of 3.1x). Net debt stands at $611M ($838M total debt minus $227M cash). Interest coverage of just 1.1x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.66 | 1.66 | 4.46 | 1.34 | 0.20 | 0.06 | 0.05 | — | 0.02 | 0.03 | 0.03 |
| Debt / EBITDA | 6.85 | 6.85 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 1.21 | 3.92 | 0.95 | -0.06 | -0.39 | -0.27 | -0.91 | -0.29 | -0.28 | -0.87 |
| Net Debt / EBITDA | 5.00 | 5.00 | — | — | — | — | — | -3.38 | — | — | — |
| Debt / FCF | — | 3.90 | — | — | — | -1.08 | — | -1.38 | — | — | — |
| Interest Coverage | 1.10 | 1.10 | -18.58 | -11.19 | — | — | — | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
Arrowhead Pharmaceuticals, Inc.'s current ratio of 4.86x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.98x to 4.86x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.86 | 4.86 | 6.74 | 3.98 | 2.92 | 2.62 | 7.92 | 2.73 | 6.37 | 3.63 | 3.53 |
| Quick Ratio | 4.86 | 4.86 | 6.74 | 3.98 | 3.07 | 2.59 | 7.82 | 2.70 | 6.27 | 3.58 | 3.48 |
| Cash Ratio | 4.70 | 4.70 | 6.60 | 3.83 | 2.71 | 2.51 | 7.76 | 2.67 | 6.19 | 3.51 | 3.33 |
| Asset Turnover | — | 0.57 | 0.00 | 0.31 | 0.35 | 0.19 | 0.17 | 0.48 | 0.14 | 0.30 | 0.00 |
| Inventory Turnover | 0.01 | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 3.00 | — | — | 2.12 | 27.07 | 3.51 | 1.43 | 7.40 | 0.79 | 172.90 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Arrowhead Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 2.4% | — | — | — |
| FCF Yield | 1.8% | 3.4% | — | — | — | 2.3% | — | 5.8% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $134M | $120M | $107M | $105M | $104M | $101M | $99M | $84M | $74M | $61M |
Compare ARWR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| ARWRYou | $9B | -5186.1 | 76.1 | 55.4 | 97.1% | 11.9% | -0.5% | 7.2% | 6.9 |
| ALNY | $44B | 142.9 | 81.4 | 94.7 | 81.8% | 13.5% | 73.3% | 19.1% | 5.3 |
| IONS | $13B | -34.1 | — | — | 98.3% | -40.5% | -70.7% | -12.2% | — |
| CRSP | $6B | -9.3 | — | — | -2642.3% | -18933.6% | -30.2% | -27.4% | — |
| BEAM | $3B | -35.1 | — | — | 84.0% | -274.6% | -8.1% | -33.6% | — |
| WVE | $2B | -19.9 | — | — | 100.0% | -101.9% | -77.9% | — | — |
| RNA | $2B | -3.0 | — | — | 77.9% | -3977.3% | -44.0% | -42.8% | — |
| STOK | $2B | -22.1 | — | — | 100.0% | -277.3% | -45.8% | -206.8% | — |
| NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
| ABUS | $895M | -12.3 | — | — | 100.0% | -1236.7% | -68.8% | -75.9% | — |
| PRME | $833M | -2.8 | — | — | 100.0% | -6787.4% | -136.9% | -260.5% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 29 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ARWR stacks up against sector leader Alnylam Pharmaceuticals, Inc..
Start ComparisonArrowhead Pharmaceuticals, Inc.'s current P/E ratio is -5186.1x. The historical average is 20.9x.
Arrowhead Pharmaceuticals, Inc.'s current EV/EBITDA is 76.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 40.8x.
Arrowhead Pharmaceuticals, Inc.'s return on equity (ROE) is -0.5%. The historical average is -76.7%.
Based on historical data, Arrowhead Pharmaceuticals, Inc. is trading at a P/E of -5186.1x. Compare with industry peers and growth rates for a complete picture.
Arrowhead Pharmaceuticals, Inc. has 97.1% gross margin and 11.9% operating margin. Operating margin between 10-20% is typical for established companies.
Arrowhead Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 6.9x, indicating high leverage. A ratio above 4x may signal elevated financial risk.